The global wilms tumor protein market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Wilms’ tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. The major factor driving the demand for the global Wilms tumor protein market during the forecast period is the increasing prevalence of leukemia across the globe. According to the Leukemia & Lymphoma Society, one person is diagnosed with leukemia approximately every 3 minutes in the US. Additionally, in 2021, an estimated combined total of 186,400 people are anticipated to be diagnosed with leukemia, lymphoma or myeloma in the US.
Furthermore, in 2021, new cases of leukemia, lymphoma and myeloma are anticipated to account for 9.8% of the estimated 1,898,160 new cancer cases. Moreover, an estimated 1,519,907 people are living with or in remission from leukemia, lymphoma, myeloma in the US. Apart from this, WT1 plays an important role in cell growth and differentiation and is highly expressed in leukemia and act as a tumor marker to detect minimal residual disease of leukemia. Hence, the increasing prevalence of leukemia is driving the demand for Wilms tumor proteins which in turn is driving the growth of the market.
To Request a Sample of our Report on Wilms Tumor Protein Market: https://www.omrglobal.com/request-sample/wilms-tumor-protein-market
Some major players in the market include SELLAS Life Sciences Group Inc., and Sumitomo Dainippon Pharma Co., Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2020, Sumitomo Dainippon Pharma Oncology, Inc., announced the dosing of the first patient with DSP-7888 in the Phase 2 expansion portion of the study evaluating the vaccine. DSP-7888 is an investigational immunotherapeutic cancer vaccine that targets WT1 in combination with checkpoint inhibitor pembrolizumab in patients with platinum-resistant ovarian cancer (PROC).
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– SELLAS Life Sciences Group Inc., and Sumitomo Dainippon Pharma Co., Ltd., among others.
(Get 15% Discount on Buying this Report)
A full Report of Wilms Tumor Protein Market is Available @ https://www.omrglobal.com/industry-reports/wilms-tumor-protein-market
Global Wilms Tumor Protein Market Report by Segment
By Type
- Elatipepimut-S
- Galinpepimut-S
- GSK-2130579A
- INO-5401
- OCV-501
- Others
By Application
- Adrenal Gland Cancer
- High-Grade Glioma
- Lung Cancer
- Peritoneal Cancer
- Leukemia
- Others
Global Wilms Tumor Protein Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
